Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Assets Average (2023 - 2025)

Silence Therapeutics' Assets Average history spans 3 years, with the latest figure at $139.1 million for Q4 2025.

  • For Q4 2025, Assets Average fell 12.8% year-over-year to $139.1 million; the TTM value through Dec 2025 reached $139.1 million, down 12.8%, while the annual FY2025 figure was $167.0 million, 3.72% up from the prior year.
  • Assets Average for Q4 2025 was $139.1 million at Silence Therapeutics, down from $156.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $457.1 million in Q4 2023 and bottomed at $139.1 million in Q4 2025.
  • The 3-year median for Assets Average is $179.5 million (2024), against an average of $244.1 million.
  • The largest annual shift saw Assets Average tumbled 65.1% in 2024 before it dropped 12.8% in 2025.
  • A 3-year view of Assets Average shows it stood at $457.1 million in 2023, then crashed by 65.1% to $159.5 million in 2024, then fell by 12.8% to $139.1 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Assets Average are $139.1 million (Q4 2025), $156.0 million (Q3 2025), and $175.3 million (Q2 2025).